Dentons Advises ADEL on Exclusive Worldwide License Agreement with Sanofi for ADEL-Y01, a novel antibody therapy for Alzheimer’s disease

Dentons provided advice to ADEL, Inc., a Korean biopharmaceutical company that specializes in finding and developing treatments for neurodegenerative diseases, including Alzheimer’s disease, regarding its exclusive worldwide license agreement with Sanofi for the creation and marketing of ADEL-Y01, a tau-targeting treatment for Alzheimer’s disease.